{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-086710","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.731290+00:00","generated_at":"2026-06-17T08:15:33.571685+00:00","sec_items":["2.02","5.08","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Disc Medicine reports FY2022 net loss $46.8M; cash $194.6M; bitopertin Phase 2 trials ongoing","bullets":["Net loss of $46.8M for FY2022 vs $36.0M in 2021; R&D expenses $33.4M, G&A $14.0M.","Cash and equivalents $194.6M as of Dec 31, 2022, up from $88.0M; expects to fund operations into 2025.","Bitopertin Phase 2 BEACON (EPP/XLP) interim data expected 1H 2023; AURORA topline data by end 2023.","DISC-0974 Phase 1b/2 in MF and NDD-CKD initiated; interim data expected end 2023.","Annual meeting June 9, 2023; record date April 14; stockholder proposal deadline April 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-086710","json":"https://secwatch.observer/filing/0001193125-23-086710.json","markdown":"https://secwatch.observer/filing/0001193125-23-086710.md","text":"https://secwatch.observer/filing/0001193125-23-086710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/0001193125-23-086710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/d463005d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:15:33.571685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51f883baa19261c4b95c8dc2519d46e44559d230","claim":"Disc Medicine, Inc. reported financial results for the full year ended December 31, 2022.","evidence_excerpt":"On March 31, 2023, Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2022 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523086710/0001193125-23-086710-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}